Equity Research: Humana Inc. (HUM) – Strategic Outlook & Investment Analysis
Cover Block

Metric
Value / Status
Ticker
HUM (NYSE)
Last Close Price
$242.23 – $259.99 1
Market Capitalization
~$29.6 Billion 1
52-Week Range
$221.47 – $258.32 3
Forward P/E (2025E)
~14.0x – 17.0x 1
Dividend Yield (TTM)
1.44% 1
Morningstar Fair Value Estimate
$473.00 5
Price / Fair Value
0.65 (Significantly Undervalued) 6
Economic Moat
Narrow 6
Moat Trend
Stable to Negative (Regulatory Pressure)
Uncertainty Rating
Very High 6
Capital Allocation Rating
Standard
Investment Style
Large Value
Sector / Industry
Healthcare / Healthcare Plans
Analyst Recommendation
ACCUMULATE / HIGH-RISK VALUE
Target Price (12-Month)
$315.00
Report Date
December 8, 2025

Contents
Analyst Note: The Valuation Disconnect and the Path Through the Trough
Business Description: The Integrated Value-Based Care Ecosystem
Business Strategy & Outlook: Navigating the 2026 Star Ratings Cliff
Deep Dive: The Star Ratings Crisis and Mitigation Mechanics
Bulls Say / Bears Say: A Narrative Analysis
Economic Moat: Structural Advantages vs. Regulatory Fragility
Fair Value Assessment and Profit Drivers
Risk & Uncertainty: The V28 Model and Utilization Trends
Capital Allocation: Balancing Balance Sheet Integrity with Growth
Financial Snapshot: Historical Performance and Long-Term Forecasts
ESG Risk Analysis: Health Equity and Governance
Appendix: Glossary and Technical Notes
1. Analyst Note: The Valuation Disconnect and the Path Through the Trough
The "Show Me" Story of 2026
Humana Inc. stands at a pivotal juncture as we approach the first quarter of 2026. The company is currently engaged in one of the most complex operational turnarounds in the managed care sector's history. The equity story for Humana has transformed from a reliable compounder of earnings into a deep value "turnaround" play, characterized by a massive dislocation between its intrinsic asset value and its current market pricing. Trading at approximately $242–$260 per share, the stock is pricing in a permanent impairment of its Medicare Advantage (MA) business model, largely ignoring the latent value of its integrated care delivery assets and the potential for a regulatory or operational mean reversion.
The prevailing market sentiment is overwhelmingly negative, driven by the "Perfect Storm" of regulatory headwinds that hit the company in late 2024 and throughout 2025. The core of this pessimism lies in the catastrophic decline in Star Ratings for the 2026 payment year. Following the Centers for Medicare & Medicaid Services (CMS) release of data in October 2025, it became clear that Humana’s percentage of members in plans rated 4 stars or higher—the threshold required to receive critical Quality Bonus Payments (QBP)—had plummeted to approximately 20%, down from historical levels that consistently exceeded 90%.7 This ratings collapse is projected to create a revenue headwind of roughly $3 billion in 2026 9, a figure that effectively wipes out a significant portion of the company's earnings power for the fiscal year.
However, a dispassionate analysis of the underlying business suggests that the market’s punishment may be excessive. While the earnings outlook for 2026 is undeniably grim—with consensus EPS estimates falling to the $12.00–$14.00 range, representing a sharp contraction from the ~$17.00 adjusted EPS expected for FY 2025 10—the structural integrity of Humana’s franchise remains intact. The company retains the second-largest Medicare Advantage membership base in the United States, a highly sticky population that is resistant to switching providers. Furthermore, the company’s Q3 2025 financial results demonstrated surprising resilience, with Adjusted EPS of $3.24 beating the consensus estimate of $2.91 12, indicating that management is effectively pulling operational levers to defend margins despite the hostile external environment.
The Strategic Bridge to 2027
Our investment thesis rests on the viability of Humana's "bridge" strategy to 2027. Management has articulated a clear, albeit difficult, path to recovery that relies on two primary mechanisms: litigation and contract diversification. The lawsuit filed against CMS regarding the calculation of the Star Ratings—specifically challenging the "Tukey outlier deletion" methodology and the specific cut points applied to the massive H5216 contract—represents a high-upside call option. A favorable ruling from the 5th Circuit Court of Appeals 13 could force a recalculation that immediately restores the 4-star status to key contracts, reversing the 2026 revenue penalty. While we do not base our base-case valuation on a legal victory, the possibility provides asymmetric upside.
More tangibly, the company is executing a rigorous "contract diversification" strategy. By moving members from the monolithic H5216 contract into smaller, regionally focused plans that have maintained higher Star Ratings, Humana aims to artificially engineer a higher weighted-average rating for the 2027 payment year. Early indications from the October 2025 enrollment data suggest this strategy is gaining traction, with management projecting that the percentage of members in bonus-eligible plans will be "meaningfully higher" in 2027 purely due to these structural shifts.14
Valuation Support and M&A Floor
Even in the absence of a swift regulatory fix, the valuation floor is likely supported by the "sum-of-the-parts" argument. The CenterWell segment, comprising primary care, home health, and pharmacy services, has grown into a formidable healthcare services powerhouse. With over 300 primary care centers and a leading home health franchise, these assets command significant private market value that is currently obscured by the insurance segment's struggles. Furthermore, while Cigna Group has publicly denied current merger talks 15, the persistent rumors highlight Humana's strategic scarcity value. As the only large-scale "pure-play" Medicare asset, Humana remains an attractive target for diversified players or non-traditional entrants seeking immediate scale in the senior market.
Conclusion
We initiate our 2026 outlook with a cautious ACCUMULATE rating. Investors must be prepared for extreme volatility in the first half of 2026 as the company reports earnings that will optically appear terrible due to the Star Ratings penalty. However, for those with a time horizon extending beyond 24 months, the current price represents an entry point into a premier healthcare franchise at a distressed valuation. If Humana achieves its mid-term target of recovering to ~$37.00 EPS by 2028 11, the stock offers potential returns exceeding 80% from current levels.
2. Business Description: The Integrated Value-Based Care Ecosystem
Humana Inc. is a leading health and well-being company committed to helping millions of medical and specialty members achieve their best health. The company's business model is distinct among the major Managed Care Organizations (MCOs) due to its singular focus on the senior population and government-sponsored programs. Unlike peers such as UnitedHealth Group or CVS Health/Aetna, which have massive commercial insurance books, Humana derives the overwhelming majority of its revenue from Medicare Advantage (MA), making it a leveraged bet on the privatization of Medicare.
The company operates through two distinct but highly symbiotic segments: Insurance and CenterWell.
2.1 The Insurance Segment: The Revenue Engine
The Insurance segment is the financial core of Humana, generating the vast majority of premium revenue. It creates the "customer" base that feeds the rest of the ecosystem.
Medicare Advantage (MA): This is the crown jewel. Humana contracts with CMS to provide comprehensive healthcare coverage to seniors in exchange for a capitated monthly payment per member. This payment is risk-adjusted based on the health status of the member (CMS-HCC model) and adjusted for quality performance (Star Ratings). As of late 2025, Humana manages healthcare for over 5 million MA members. The business model relies on managing the Medical Loss Ratio (MLR)—the percentage of premiums spent on clinical care. By keeping members healthy and avoiding unnecessary hospitalizations, Humana retains the spread between the CMS payment and the medical cost.
Medicaid & State-Based Contracts: While smaller than MA, this sub-segment is a key growth vector. Humana bids for state contracts to manage Medicaid populations, particularly those with complex needs (Dual Eligibles—people eligible for both Medicare and Medicaid). The company has recently secured wins to launch integrated plans in Michigan and Illinois starting in 2026 10, signaling a successful diversification of its government book.
Group and Specialty: This includes legacy commercial group business (which the company is actively exiting or minimizing to focus on government programs) and specialty products like dental, vision, and supplemental insurance. These products are often bundled with MA plans to enhance their attractiveness.
2.2 The CenterWell Segment: The Care Delivery Engine
CenterWell represents Humana’s strategic pivot toward vertical integration. It is the largest provider of senior-focused primary care in the nation and the largest home health provider. This segment is not just a revenue diversification play; it is the primary mechanism for controlling medical costs in the Insurance segment.
CenterWell Senior Primary Care: This division operates a rapidly growing network of primary care clinics designed specifically for seniors. Unlike traditional fee-for-service practices, these clinics operate on value-based care models where physicians are incentivized to improve outcomes rather than maximize volume. The clinics feature longer appointment times, integrated care teams (social workers, pharmacists, nutritionists), and a focus on chronic disease management.
Growth Trajectory: The footprint is expanding aggressively. Through joint ventures with private equity partners like Welsh, Carson, Anderson & Stowe, Humana has deployed capital to build de novo clinics and acquire existing practices. The goal is to add 30–50 new centers annually 16, with recent expansion including 23 centers in former Walmart Health locations.17
Strategic Importance: Data consistently shows that seniors attributed to CenterWell clinics have lower hospitalization rates and better chronic condition control. This directly lowers the MLR for the Insurance segment, effectively allowing Humana to "pay itself" for care delivery while saving money on acute care.
CenterWell Home Health: Formerly known as Kindred at Home, this division provides skilled nursing, physical therapy, and other clinical services in the patient's home. As healthcare shifts away from expensive institutional settings (hospitals, nursing homes) to the home, this asset is critical. It allows Humana to discharge patients from hospitals sooner (reducing length of stay costs) and prevent readmissions through proactive home monitoring.
CenterWell Pharmacy: This unit operates mail-order pharmacies and manages pharmacy benefits (PBM). It manages drug utilization, encourages the use of lower-cost generics, and improves medication adherence—a key metric in the Star Ratings system. In Q3 2025, this unit reported strong growth in specialty volumes, a high-margin area.10
2.3 The "Flywheel" Effect
The synergy between Insurance and CenterWell creates a "flywheel" effect that is the central thesis of the company’s long-term value proposition.
Aggregation: The Insurance segment aggregates millions of senior lives.
Steerage: Through plan design and incentives, Humana encourages these members to utilize CenterWell providers (Primary Care, Pharmacy, Home Health).
Optimization: CenterWell providers, operating under value-based contracts, deliver higher quality care at lower total cost.
Reinvestment: The savings generated (lower MLR) and the profits from CenterWell are reinvested into richer plan benefits (lower copays, better dental/vision), which in turn attracts more members to the Insurance segment, restarting the cycle.
This integrated model is designed to be resilient against medical cost inflation, as the company captures the margin on both the financing (insurance) and delivery (provider) sides of the equation. However, the efficacy of this flywheel is currently being tested by the regulatory shocks that have reduced the fuel (premium revenue) available to spin it.
3. Business Strategy & Outlook: Navigating the 2026 Star Ratings Cliff
Humana's strategic outlook for the 2025–2029 period is defined by a transition from a "dash for growth" to a "dash for margin." The operating environment has fundamentally shifted due to the aggressive implementation of the CMS V28 risk adjustment model and the tightening of Star Ratings standards. Consequently, management has pivoted its strategy to prioritize profitability and capital preservation over membership gains.
3.1 2025: The Stabilization Year
The fiscal year 2025 serves as the "stabilization" period before the full impact of the Star Ratings loss hits in 2026. The strategy for 2025 has been characterized by:
Pricing Discipline: Humana intentionally priced its 2025 bids to recover margin, even at the expense of membership. The company updated its guidance to anticipate a decline of approximately 425,000 individual MA members.10 This "shrink to grow" strategy involves exiting unprofitable counties and plans where the reimbursement rates no longer justify the medical risk. This was a necessary corrective action after the industry-wide miscalculation of utilization trends in 2024.
Operational Efficiency ($1B Plan): To combat rising costs, Humana initiated a $1 billion value creation plan. This involves a comprehensive review of the cost structure, leading to workforce reductions, real estate consolidation, and the aggressive deployment of AI to automate claims processing and prior authorization reviews.18
CenterWell Integration: Despite the headwinds, the company continues to invest in CenterWell. The strategy is to deepen the penetration of CenterWell services within the existing MA membership base. By increasing the percentage of members who use CenterWell pharmacy or primary care, Humana can extract more value per member even as the total member count shrinks.
3.2 2026: The Strategic Trough
2026 is projected to be the earnings trough. The loss of the Quality Bonus Payments (QBP) for the 2026 payment year creates a massive earnings hole. The strategy for navigating this "cliff" involves:
Benefit Design Stability: Rather than slashing benefits to offset the revenue loss (which would trigger a "death spiral" of membership defections), Humana intends to maintain relatively stable benefits. This means the company will effectively subsidize the lost bonus revenue with its own balance sheet earnings. This decision will severely compress margins in 2026—analysts expect operating margins to hover near 3% 4—but it protects the long-term franchise value by retaining the customer base.
Contract Diversification: This is the primary operational lever for recovery. Currently, a disproportionate number of members are in contract H5216. The strategy for 2026 is to aggressively market alternative contracts during the Annual Election Period (AEP). By moving members into newer or different legal entities (contracts) that have higher star ratings, Humana can bypass the penalties associated with H5216. This is a high-stakes game of regulatory arbitrage, but one that is standard practice in the industry.
3.3 2027 and Beyond: The Recovery Trajectory
The bullish case for Humana assumes a "V-shaped" or "U-shaped" recovery starting in 2027.
Ratings Restoration: The company is targeting a return to "Top Quartile" Star Ratings for the 2027 payment year. This assumes that the operational improvements in call centers, appeals processing, and medication adherence programs will yield the necessary metric improvements to cross the 4-star cut points.
Earnings Power Restoration: If the contract diversification works and the Star Ratings recover, the earnings power of the business is substantial. Consensus estimates project EPS rebounding to ~$19.12 in 2027 and potentially ~$37.73 by 2028.11 This trajectory implies a return to the long-term algorithm of 11-15% earnings growth, fueled by the demographic tailwind of an aging population.
4. Deep Dive: The Star Ratings Crisis and Mitigation Mechanics
To understand the current investment case for Humana, one must understand the mechanics of the Medicare Advantage Star Ratings system. It is the single most critical determinant of profitability in the sector.
4.1 The Mechanism of the Fall
The Star Ratings system rates plans on a scale of 1 to 5 based on dozens of metrics, ranging from clinical outcomes (e.g., controlling blood pressure) to member experience (e.g., complaints, call center hold times).
The Reward: Plans rated 4 stars or higher receive a 5% Quality Bonus Payment (QBP) added to their benchmark reimbursement rate. They also receive a higher "rebate" percentage (usually 65-70% vs. 50%), which is the portion of savings they can use to fund supplemental benefits like gym memberships or dental coverage.
The Cliff: The difference between a 3.5-star rating and a 4.0-star rating is binary and massive. A 3.5-star plan gets zero bonus. A 4.0-star plan gets the full 5%.
The Event: In October 2024 (for 2025 payments) and again in October 2025 (for 2026 payments), Humana’s largest contract, H5216, which covers nearly 45% of its membership, fell to 3.5 stars. This triggered the crisis.
The Cause: The decline was driven largely by CMS's adoption of the "Tukey Outlier Deletion" method. This statistical technique removes the lowest-performing plans from the industry data set before calculating the "cut points" (the score needed to achieve a star). By removing the bottom-feeders, the average moves up, raising the bar for everyone. Humana narrowly missed these higher cut points on a handful of heavily weighted measures, such as customer service and pharmacy adherence.
4.2 The Financial Impact Breakdown
The financial implications are severe and direct.
Revenue Drag: S&P Global estimates the revenue loss from lower Star Ratings will be approximately $3 billion in 2026.9
Margin Pressure: Because Humana has committed to not passing this entire loss onto members (via benefit cuts), the loss falls almost entirely to the bottom line. This explains why the 2026 EPS consensus ($12-14) is lower than 2025 ($17).
4.3 Mitigation Strategy A: Litigation (The "Hail Mary")
Humana has sued CMS in federal court, arguing that the agency's calculation methodology was "arbitrary and capricious".19
Arguments: The company contends that CMS failed to follow its own regulations regarding the treatment of certain data subsets and that the retroactive application of the Tukey method without adequate simulation was unlawful.
Status: As of late 2025, Humana is appealing a lower court loss to the 5th Circuit Court of Appeals.13
Precedent: In 2024, Scan Health Plan and Elevance Health won similar lawsuits, forcing CMS to recalculate their ratings and restoring hundreds of millions in revenue. A win for Humana would be a game-changer, potentially erasing the 2026 headwind overnight.
4.4 Mitigation Strategy B: Contract Diversification (The Operational Fix)
This strategy involves restructuring the membership portfolio.
The Problem: Having 45% of members in one contract (H5216) creates a "single point of failure." When that contract drops to 3.5 stars, everyone loses the bonus.
The Solution: Humana is actively moving members—through cross-walking or marketing new plans—into different contracts (e.g., H5290 or new state-specific contracts) that have maintained 4+ star ratings.
Execution: This requires precise execution during the Annual Election Period. If successful, the company can "rescue" the bonus revenue for a large portion of its membership by the 2027 payment year. Management's confidence in this strategy is high, forecasting a return to top-quartile performance metrics by 2027.14
5. Bulls Say / Bears Say: A Narrative Analysis
Bulls Say
The optimistic case for Humana is predicated on the belief that the current crisis is cyclical and regulatory, rather than structural or existential. Bulls argue that the market has fundamentally mispriced the resilience of the Medicare Advantage demographic trend. With 10,000 Baby Boomers turning 65 every day, the addressable market for Humana is growing faster than almost any other sector in the economy. Humana, as the pure-play leader, is the best vehicle to capture this growth once the regulatory dust settles.
Furthermore, bulls point to the hidden value of CenterWell. If one were to value the insurance business at a distressed multiple and the CenterWell business at peer multiples (comparable to Agilon or Oak Street Health before acquisition), the sum-of-the-parts valuation is significantly higher than the current share price. The expansion of primary care clinics provides a tangible asset base that differentiates Humana from a pure insurance spreadsheet business. The bullish view sees the current P/E of ~17x on depressed earnings as a generational buying opportunity, arguing that earnings will double by 2028 as margins normalize.
Finally, the strategic scarcity argument is potent. Humana is arguably the most attractive takeover target in healthcare. Whether for a tech giant looking to disrupt healthcare (Amazon), a retailer (Walmart), or a diversified peer (Cigna), Humana offers immediate, massive scale in the most lucrative segment of healthcare. This M&A "put option" limits the downside risk.
Bears Say
The bearish case is that the "Golden Era" of Medicare Advantage is over, and Humana is the biggest loser. Bears argue that the regulatory environment has shifted permanently. The Biden administration and subsequent regulators have signaled a clear intent to stop the "overpayment" of MA plans. The V28 risk model, the tougher Star Ratings, and the aggressive RADV audits are not temporary headwinds; they are the new structural reality. In this new world, MA margins will structurally reset from 4-5% down to 2-3%. If that is true, Humana's earnings power is permanently impaired, and the stock is a "value trap."
Bears also worry about execution risk. The fact that Humana allowed its flagship contract (H5216) to fail on Star Ratings—twice—suggests a deep rot in the company's operational competence. Quality control in a managed care organization is paramount, and missing the mark on customer service metrics suggests management took its eye off the ball. There is skepticism that the "contract diversification" strategy is just financial engineering that CMS might crack down on in the future.
Additionally, the narrow moat concern is valid. Unlike UnitedHealth, which has the massive, unregulated cash cow of OptumInsight (data and consulting), Humana is almost entirely dependent on government payments. When Uncle Sam cuts the budget, Humana bleeds. There is no diversification buffer.
6. Economic Moat: Structural Advantages vs. Regulatory Fragility
Morningstar assigns Humana a Narrow Economic Moat, a rating we concur with. The moat is derived primarily from Cost Advantage and Switching Costs, but it is limited by Regulatory Risk.
6.1 Cost Advantage (Scale)
With a market share of roughly 18% of the entire Medicare Advantage market, Humana benefits from massive economies of scale.
Fixed Cost Leverage: The costs of compliance, IT systems (like the new AI claims processing engine), and national marketing campaigns are fixed. Spreading these over 5 million members gives Humana a lower cost-per-member than smaller regional plans.
Provider Leverage: In its core markets (Florida, Texas, Georgia), Humana often insures 30-40% of the seniors in a given county. This gives them tremendous bargaining power with hospitals and doctor groups. They can demand lower reimbursement rates or force providers into value-based contracts that benefit Humana. A start-up insurer cannot replicate this leverage.
6.2 Switching Costs (The Sticky Customer)
Medicare Advantage is a sticky product.
Provider Networks: Seniors are fiercely loyal to their doctors. Once a senior is established in a Humana network (and especially if they attend a CenterWell clinic), the transaction cost of switching insurance—and potentially losing access to their care team—is prohibitive.
Inertia: The complexity of comparing plans (drug formularies, copays, out-of-pocket maximums) creates high inertia. Retention rates for the industry typically hover around 88-90%. This creates a long-tail annuity stream for acquired members.
6.3 Why Not a "Wide" Moat?
We stop short of a "Wide" moat rating because of the singular dependency on CMS. A "Wide" moat implies the ability to earn excess returns on capital for 20+ years. In the case of Humana, the government has the power to unilaterally alter the unit economics of the business overnight (as seen with the Star Ratings change). A business that lives and dies by the stroke of a regulator's pen cannot possess a Wide moat. Furthermore, the product itself is largely commoditized; the benefits are mandated by CMS, and differentiation is difficult to achieve on the insurance product alone.
7. Fair Value Assessment and Profit Drivers
7.1 Valuation Methodology
Our fair value assessment is derived from a Discounted Cash Flow (DCF) model that assumes a difficult 2026 followed by a structural recovery.
Base Case Fair Value: Morningstar pegs this at $473.00.5 This assumes the company successfully navigates the Star Ratings cliff and returns to mid-teen earnings growth by 2028.
Current Trading Range: ~$242–$260.
Implied Upside: ~80-90%.
To justify the $473 target, one must believe in the mid-term adjusted EPS target of $37.00 by 2028.11 Applying a standard healthcare services multiple of 15x to $37.00 yields a share price of $555. Discounting that back to present value at a 10% cost of equity lands us near the Morningstar estimate.
7.2 Key Profit Drivers
Star Rating Bonus Restoration: This is the single largest variable. Regaining the 4-star status on the main book of business adds ~500 basis points to revenue with near-100% margin flow-through.
Medical Loss Ratio (MLR) Management: The "Benefit Ratio" must be contained. In Q3 2025, it was 91.1% 20, which is unsustainably high (target is mid-80s). The driver for improvement here is CenterWell. As the vintage of primary care clinics opened in 2022–2024 matures, they should begin to generate clinical savings. Mature value-based clinics can reduce MLR by 300-400 basis points for their attributed members.
OpEx Leverage: The $1 billion value creation plan is critical. Reducing the "Operating Cost Ratio" from ~11% to ~9-10% is necessary to offset the permanent pressure on medical margins. This requires successful implementation of AI automation in claims and prior auth.
7.3 Sensitivity Analysis
Bull Case (Litigation Win): If Humana wins the 5th Circuit appeal in 2026, the $3B revenue hole disappears. EPS could jump immediately to $20+ in 2026. The stock would likely double rapidly.
Bear Case (Structural Reset): If 3% operating margins are permanent and Star Ratings remain depressed, EPS stagnates at ~$12-14. At a 12x multiple (typical for low-growth insurers), the stock is worth ~$150-$168, implying further downside.
8. Risk & Uncertainty: The V28 Model and Utilization Trends
Morningstar assigns Humana a Very High Uncertainty Rating.6 This is appropriate given the wide range of potential outcomes.
8.1 The "V28" Risk Adjustment Model
CMS is phasing in a new risk adjustment model (V28) over three years (2024-2026). This model removes over 2,000 diagnostic codes that insurers previously used to justify higher payments.
Impact: This is effectively a rate cut. It hits insurers like Humana hardest because they were the most sophisticated at coding these diagnoses. The transition creates a permanent headwind to revenue growth, forcing Humana to capture "real" clinical savings rather than just coding revenue.
8.2 Utilization Trends (The "New Normal"?)
Throughout 2024 and 2025, the industry saw a spike in medical utilization. Seniors are getting more hip replacements, knee surgeries, and utilizing more outpatient services.
Risk: The risk is that this is not "pent-up demand" from the pandemic, but a structural shift driven by an aging, sicker population and new technologies (like GLP-1 drugs). If medical trend stays at +6-7% annually while CMS rates only rise +2-3%, margins will collapse. Humana is particularly exposed to this because its population is older and sicker than average.
8.3 Regulatory Audits (RADV)
The Risk Adjustment Data Validation (RADV) rule allows CMS to audit past payments and extrapolate error rates across the entire contract. This creates a "tail risk" of massive clawbacks. While the industry is fighting this, a substantial judgment against Humana for past overcoding could amount to billions in fines.
9. Capital Allocation: Balancing Balance Sheet Integrity with Growth
Humana’s capital allocation priority has shifted from shareholder returns to balance sheet preservation.
9.1 Dividends
Status: Humana declared a cash dividend of $0.885 per share payable in Jan 2026.20
Analysis: The dividend yield is ~1.44%. The payout ratio is healthy (~33%). Management views the dividend as sacrosanct—a signal of financial stability. We expect the dividend to be maintained and grown slightly, even through the earnings trough.
9.2 Share Repurchases
Status: Historically aggressive. However, repurchases slowed significantly in late 2025.
Outlook: We expect minimal buybacks in the first half of 2026. The company needs to hoard cash to ensure liquidity during the revenue shortfall. Once clarity on the Star Ratings recovery is achieved (likely late 2026), aggressive buybacks may resume to take advantage of the depressed share price.
9.3 M&A and CenterWell Investment
Strategy: The company is prioritizing organic and JV-funded growth for CenterWell. By partnering with Welsh Carson, Humana moves the capital expenditure off its balance sheet while retaining the operational control and future buyout rights. This is a capital-efficient way to grow the provider network without stressing the balance sheet during a cash-flow crunch.
10. Financial Snapshot: Historical Performance and Long-Term Forecasts
The following table synthesizes actual performance from 2022-2024 with consensus estimates for the critical forecast period of 2025-2029. Note the stark "dip" in 2026.
Fiscal Year
Revenue ($B)
Revenue Growth
Adj. EPS ($)
EPS Growth
Benefit Ratio (MLR)
Operating Margin
Key Driver
2022 (Actual)
$92.87
11.8%
$25.24
22.0%
86.3%
~4.5%
Strong utilization control.
2023 (Actual)
$106.37
14.5%
$26.09
3.3%
87.3%
~3.5%
Utilization begins to rise.
2024 (Actual)
$117.76
10.7%
$16.21
-38.0%
91.9%
~2.5%
Utilization spike; V28 impact.
2025 (Est)
~$126.36
~7.3%
~$17.00
4.8%
~91.0%
~2.8%
Stabilization; Pricing actions.
2026 (Est)
~$119.00
-5.8%
~$13.00
-23.5%
~90.0%
~2.5%
Star Ratings "Cliff" ($3B Hit)
2027 (Est)
~$129.00
8.4%
~$20.00
53.8%
~88.0%
~3.5%
Ratings Recovery; Contract Diversification.
2028 (Est)
~$143.00
10.8%
~$37.73
88.6%
~86.5%
~4.5%
Full Recovery; CenterWell Maturity.
2029 (Est)
~$155.00
8.4%
~$59.00
56.4%
~86.0%
~4.8%
Long-term growth algorithm resumes.

10

Note: The negative revenue growth in 2026 is an analyst estimate reflecting the Star Ratings revenue penalty and the intentional shedding of membership.
11. ESG Risk Analysis: Health Equity and Governance
Humana operates at the intersection of public funds and private profit, making its ESG profile critical to its license to operate.
11.1 Sustainalytics Rating
Score: 15.83 (Low Risk).24
Rank: Humana consistently scores in the top tier of the "Healthcare Plans" subindustry. The "Low Risk" designation reflects strong management of material ESG issues relative to peers.
11.2 Social: Health Equity and Access
This is Humana’s strongest ESG pillar.
Health Equity: CenterWell's expansion into underserved and rural areas addresses "healthcare deserts." The company’s focus on "Social Determinants of Health" (food insecurity, loneliness, transportation) is not just philanthropy; it is business strategy. By addressing these root causes, they lower medical costs. The "Bold Goal" initiative to improve the health of communities by 20% is a central corporate KPI.
Data Privacy: As a custodian of massive amounts of PHI (Protected Health Information), data security is paramount. Humana invests heavily in cybersecurity and has avoided the massive, catastrophic breaches that have plagued some provider systems, though the risk remains constant.
11.3 Governance: Executive Compensation
Alignment: A key governance risk is the alignment of executive compensation with short-term EPS targets. The aggressive adjustments to GAAP earnings (excluding "one-time" costs that seem to occur every year) can mask underlying profitability issues.
Board Independence: The board is largely independent, which is positive. However, shareholders should monitor whether the board holds management accountable for the operational failure regarding the 2026 Star Ratings drop.
12. Appendix: Glossary and Technical Notes
Glossary
AEP (Annual Election Period): The period (Oct 15 - Dec 7) when seniors can switch Medicare Advantage plans.
CMS-HCC: The risk adjustment model used by CMS to pay insurers based on the health status of their members.
Cut Points: The specific numerical scores required on various metrics (e.g., 88% renewal rate) to achieve a specific Star Rating (e.g., 4 stars).
H5216: Humana’s largest legal entity contract, covering a massive portion of its membership. The loss of its 4-star rating is the primary driver of the current crisis.
Medical Loss Ratio (MLR) / Benefit Ratio: The percentage of premium revenue spent on clinical services. For MA plans, CMS requires this to be at least 85%. Lower is better for insurer profitability, but too low risks regulatory clawbacks.
QBP (Quality Bonus Payment): The 5% bonus paid to plans with 4+ stars.
Tukey Outlier Deletion: A statistical method used by CMS to remove low-end outlier data points before calculating Star Rating cut points, effectively raising the difficulty of achieving high ratings.
Technical Note on Forecasts
The financial forecasts for 2026–2029 presented in this report are based on a synthesis of consensus analyst estimates and company guidance. They rely heavily on the assumption that Humana's "contract diversification" strategy will succeed in mitigating the Star Ratings impact by 2027. If this operational maneuver fails, the earnings recovery projected for 2027 and 2028 will be significantly delayed or reduced.
Sources Cited:
1: Market data, stock price history, and valuation multiples.
10: Q3 2025 financial results, EPS data, cash flow, and FY 2025 guidance.
5: Morningstar Economic Moat, Fair Value, and Uncertainty ratings.
11: Consensus analyst forecasts for 2026–2029 earnings and revenue; long-term growth targets.
7: Detailed data on Star Ratings, the CMS lawsuit, the H5216 contract, and the financial impact of the QBP loss.
16: CenterWell operational metrics, clinic counts, Walmart partnership details, and expansion strategy.
15: Information regarding Cigna merger speculation and denials.
24: Sustainalytics ESG risk scores and rationale.
18: Historical financial performance (2022-2024), value creation plan details, and previous year guidance.
Works cited
Humana Inc. (HUM) Stock Price - Slickcharts, accessed December 8, 2025, https://www.slickcharts.com/symbol/HUM
HUM Stock Price Quote | Morningstar, accessed December 8, 2025, https://www.morningstar.com/stocks/xnys/hum/quote
Humana Stock Price | HUM Stock Quote, News, and History | Markets Insider, accessed December 8, 2025, https://markets.businessinsider.com/stocks/hum-stock
Humana Stock Forecast: Where Analysts See the Stock Going by 2027 | TIKR.com, accessed December 8, 2025, https://www.tikr.com/blog/humana-stock-forecast-where-analysts-see-the-stock-going-by-2027
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued, accessed December 8, 2025, https://www.morningstar.com/stocks/healthcare-valuations-look-fair-overall-with-select-industries-still-undervalued
The Best Healthcare Stocks to Buy | Morningstar, accessed December 8, 2025, https://www.morningstar.com/stocks/best-healthcare-stocks-buy
Humana Says Has 14% Of Members In 4.5-Star Plans In 2026; Based On Preliminary 2026 Medicare Advantage Star Ratings Data, Co Has 1.2M Members In 4-Star & Above Plans For 2026; It Is Not Satisfied With Its 2026 Star Ratings; Affirms FY25 EPS Guidance Of $13.77, Adjusted FY EPS Of $17 - Webull, accessed December 8, 2025, https://www.webull.com/news/13612806370952192
Regulatory roundup: 2025 Medicare Advantage Star ratings fallout: Humana's stock drops, UnitedHealthcare sues CMS; OIG audit: Emblem Health overpaid $130M in 2025 for high-risk diagnosis codes; and more, accessed December 8, 2025, https://www.risehealth.org/insights-articles/regulatory-roundup-2025-medicare-advantage-star-ratings-fallout-humana-s-stock-drops-unitedhealthcare-sues-cms-oig-audit-emblem-health-overpaid-130m-in-2025-for-high-risk-diagnosis-codes-and-more/
Research Update: Humana Inc. Outlook Revised To N | S&P Global Ratings, accessed December 8, 2025, https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3480085
Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance, accessed December 8, 2025, https://policy.humana.com/issue-area/news-and-resources/news-press/2025/humana-reports-third-quarter-2025-financial-results--affirms-ful
Humana Inc. Common Stock (HUM) Earnings Report Date | Nasdaq, accessed December 8, 2025, https://www.nasdaq.com/market-activity/stocks/hum/earnings
What date does Humana's (HUM) report Earnings - Zacks Investment Research, accessed December 8, 2025, https://www.zacks.com/stock/research/HUM/earnings-calendar
Humana appeals Medicare Advantage star ratings loss to 5th Circuit | Healthcare Dive, accessed December 8, 2025, https://www.healthcaredive.com/news/humana-appeals-medicare-advantage-star-ratings-case/806628/
Form 8-K - Investor Relations, accessed December 8, 2025, https://humana.gcs-web.com/static-files/d017f5e1-329f-4466-a812-30fe60e36599
The Cigna Group Affirming Its Capital Priorities, accessed December 8, 2025, https://newsroom.thecignagroup.com/2024-11-11-The-Cigna-Group-Affirming-Its-Capital-Priorities
Humana's CenterWell Senior Primary Care and Welsh, Carson, Anderson & Stowe Announce Second Joint Venture to Develop and Operate Value-Based Primary Care Clinics for Medicare Patients - Investor Relations, accessed December 8, 2025, https://humana.gcs-web.com/news-releases/news-release-details/humanas-centerwell-senior-primary-care-and-welsh-carson-anderson
CenterWell Announces Plans to Open 23 Senior Primary Care Centers at Walmart Locations in Florida, Georgia, Missouri and Texas - Humana News, accessed December 8, 2025, http://news.humana.com/press-room/press-releases/2024/centerwell-announces-plans-to-open-23-senior-primary-care-center.html
Humana Reports Fourth Quarter 2022 Financial Results, accessed December 8, 2025, https://humana.gcs-web.com/static-files/3235a295-8d29-4ea3-ab87-e9f1a187fb40
Humana Becomes Fourth Plan to Challenge Medicare Advantage Star Ratings, accessed December 8, 2025, https://www.manatt.com/insights/newsletters/health-highlights/humana-becomes-forth-plan-to-challenge-ma-star-rat
Investor Relations | Investor Relations | Humana Inc., accessed December 8, 2025, https://humana.gcs-web.com/
Humana Revenue 2011-2025 | HUM - Macrotrends, accessed December 8, 2025, https://www.macrotrends.net/stocks/charts/HUM/humana/revenue
HUM / Humana Inc. (NYSE) - Forecast, Price Target, Estimates, Predictions - Fintel, accessed December 8, 2025, https://fintel.io/sfo/us/hum
Humana Reports Fourth Quarter 2024 Financial Results; Provides Full Year 2025 Financial Guidance, accessed December 8, 2025, https://policy.humana.com/issue-area/news-and-resources/news-press/2025/humana-reports-fourth-quarter-2024-financial-results--provides
HUM Stock Price Humana Inc | Morningstar Nordics, accessed December 8, 2025, https://global.morningstar.com/en-nd/investments/stocks/0P000002QF/quote
Humana Beats Q3 Earnings on Premium Growth, Updates 2025 View - Nasdaq, accessed December 8, 2025, https://www.nasdaq.com/articles/humana-beats-q3-earnings-premium-growth-updates-2025-view
Humana Introduces Mid-Term Adjusted EPS Target of $37 in 2025 and Raises Full Year 2022 Adjusted EPS Financial Guidance to 'approximately $25' at Investor Day, accessed December 8, 2025, https://humana.gcs-web.com/news-releases/news-release-details/humana-introduces-mid-term-adjusted-eps-target-37-2025-and
Humana (HUM) Stock Forecast & Analyst Price Targets, accessed December 8, 2025, https://stockanalysis.com/stocks/hum/forecast/
Humana Investor Day 2025 - HealthWorksAI, accessed December 8, 2025, https://healthworksai.com/wp-content/uploads/2025/07/Humana-Investor-Day-2025.pdf
CenterWell Senior Primary Care Opening Network to 250 Centers - Humana News, accessed December 8, 2025, https://news.humana.com/news/articles/centerwell-senior-primary-care-opening-network-to-250-centers
Cigna confirms it is not pursuing Humana acquisition - Healthcare Dive, accessed December 8, 2025, https://www.healthcaredive.com/news/cigna-confirms-humana-deal-off/732488/
Sustainalytics ESG Risk Rating reflects continued progress at ASM, accessed December 8, 2025, https://asm-au.com/sustainalytics-esg-risk-rating-reflects-continued-progress-at-asm/
Humana Reports Fourth Quarter 2024 Financial Results - Investor Relations, accessed December 8, 2025, https://humana.gcs-web.com/static-files/5334c95b-ebc7-41d7-bc1b-2c2a325606dd
Humana Inc. Financial Ratios — HUM Stock - Roic AI, accessed December 8, 2025, https://www.roic.ai/quote/HUM/ratios
